NCT01650155View on ClinicalTrials.gov

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Healthy
Interventions
DRUG

BI 1005273 s.c.

injection

DRUG

BI 105273 i.v. Placebo

infusion

DRUG

BI 1005273 s.c. Placebo

injection

DRUG

BI 1005273 i.v.

infusion

Trial Locations (1)

Unknown

1294.1.1 Boehringer Ingelheim Investigational Site, Berlin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY